BACKGROUND: BRCA germline mutations are being targeted for development of PARP inhibitors. BRCA genes collaborate with several others in the Fanconi Anemia (FA) pathway. We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent. METHODS: Patients underwent FA functional screening for the presence (or lack) of tumor FancD2 nuclear foci formation on their archival tumor material, utilizing a newly developed method (Fanconi Anemia triple-stain immunofluorescence [FATSI]), performed in a Clinical Laboratory Improvement Amendments-certified laboratory. FATSI-negative patients were selected for enrollment in a two-arm dose escalation trial of veliparib, or veliparib/mitomycin-C (MMC). RESULTS: One hundred eighty-five of 643 (28.7%) screened patients were FATSI-negative. Sixty-one received veliparib or veliparib/MMC through 14 dose levels. Moderate/severe toxicities included fatigue (DLT at veliparib 400mg BID), diarrhea, and thrombocytopenia. Recommended doses are 300mg BID veliparib and veliparib 200mg BID for 21 days following 10mg/m(2) MMC every 28 days. Six antitumor responses occurred, five in the combination arm (3 breast, 1 ovarian, 1 endometrial [uterine], and 1 non-small cell lung cancer). Two patients have received 36 and 60 cycles to date. BRCA germline analysis among 51 patients revealed five deleterious mutations while a targeted FA sequencing gene panel showed missense/nonsense mutations in 29 of 49 FATSI-negative tumor specimens. CONCLUSIONS: FATSI screening showed that a substantial number of patients' tumors have FA functional deficiency, which led to germline alterations in several patients' tumors. Veliparib alone or with MMC was safely administered to these patients and produced clinical benefit in some. However, a better understanding of resistance mechanisms in this setting is needed.
BACKGROUND:BRCA germline mutations are being targeted for development of PARP inhibitors. BRCA genes collaborate with several others in the Fanconi Anemia (FA) pathway. We screened cancerpatients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent. METHODS:Patients underwent FA functional screening for the presence (or lack) of tumorFancD2 nuclear foci formation on their archival tumor material, utilizing a newly developed method (Fanconi Anemia triple-stain immunofluorescence [FATSI]), performed in a Clinical Laboratory Improvement Amendments-certified laboratory. FATSI-negative patients were selected for enrollment in a two-arm dose escalation trial of veliparib, or veliparib/mitomycin-C (MMC). RESULTS: One hundred eighty-five of 643 (28.7%) screened patients were FATSI-negative. Sixty-one received veliparib or veliparib/MMC through 14 dose levels. Moderate/severe toxicities included fatigue (DLT at veliparib 400mg BID), diarrhea, and thrombocytopenia. Recommended doses are 300mg BIDveliparib and veliparib 200mg BID for 21 days following 10mg/m(2) MMC every 28 days. Six antitumor responses occurred, five in the combination arm (3 breast, 1 ovarian, 1 endometrial [uterine], and 1 non-small cell lung cancer). Two patients have received 36 and 60 cycles to date. BRCA germline analysis among 51 patients revealed five deleterious mutations while a targeted FA sequencing gene panel showed missense/nonsense mutations in 29 of 49 FATSI-negative tumor specimens. CONCLUSIONS: FATSI screening showed that a substantial number of patients' tumors have FA functional deficiency, which led to germline alterations in several patients' tumors. Veliparib alone or with MMC was safely administered to these patients and produced clinical benefit in some. However, a better understanding of resistance mechanisms in this setting is needed.
Authors: Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter Journal: Nat Genet Date: 2006-12-31 Impact factor: 38.330
Authors: Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg Journal: Nat Genet Date: 2010-04-18 Impact factor: 38.330
Authors: Louise J Barber; Shahneen Sandhu; Lina Chen; James Campbell; Iwanka Kozarewa; Kerry Fenwick; Ioannis Assiotis; Daniel Nava Rodrigues; Jorge S Reis Filho; Victor Moreno; Joaquin Mateo; L Rhoda Molife; Johann De Bono; Stan Kaye; Christopher J Lord; Alan Ashworth Journal: J Pathol Date: 2013-02 Impact factor: 7.996
Authors: Wenrui Duan; Li Gao; Brittany Aguila; Arjun Kalvala; Gregory A Otterson; Miguel A Villalona-Calero Journal: Front Oncol Date: 2014-12-19 Impact factor: 6.244
Authors: Agata Smogorzewska; Shuhei Matsuoka; Patrizia Vinciguerra; E Robert McDonald; Kristen E Hurov; Ji Luo; Bryan A Ballif; Steven P Gygi; Kay Hofmann; Alan D D'Andrea; Stephen J Elledge Journal: Cell Date: 2007-04-05 Impact factor: 41.582
Authors: Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes Journal: Proc Natl Acad Sci U S A Date: 2007-04-09 Impact factor: 11.205
Authors: Anneleen Daemen; Denise M Wolf; James E Korkola; Obi L Griffith; Jessica R Frankum; Rachel Brough; Lakshmi R Jakkula; Nicholas J Wang; Rachael Natrajan; Jorge S Reis-Filho; Christopher J Lord; Alan Ashworth; Paul T Spellman; Joe W Gray; Laura J van't Veer Journal: Breast Cancer Res Treat Date: 2012-08-09 Impact factor: 4.872
Authors: Julia Manzo; Shannon Puhalla; Shalu Pahuja; Fei Ding; Yan Lin; Leonard Appleman; Hussein Tawbi; Ronald Stoller; James J Lee; Brenda Diergaarde; Brian F Kiesel; Jing Yu; Antoinette R Tan; Chandra P Belani; Helen Chew; Agustin A Garcia; Robert J Morgan; Andrea E Wahner Hendrickson; Daniel W Visscher; Rachel M Hurley; Scott H Kaufmann; Elizabeth M Swisher; Steffi Oesterreich; Tiffany Katz; Jiuping Ji; Yiping Zhang; Ralph E Parchment; Alice Chen; Wenrui Duan; Vincent Giranda; Stacie P Shepherd; S Percy Ivy; Edward Chu; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2022-04-18 Impact factor: 3.288
Authors: Miguel A Villalona-Calero; John P Diaz; Wenrui Duan; Zuanel Diaz; Eric D Schroeder; Santiago Aparo; Troy Gatcliffe; Federico Albrecht; Siddhartha Venkatappa; Victor Guardiola; Sara Garrido; Muni Rubens; Fernando DeZarraga; Hao Vuong Journal: Biomark Res Date: 2022-06-03
Authors: Shreya M Shah; Elena V Demidova; Randy W Lesh; Michael J Hall; Mary B Daly; Joshua E Meyer; Martin J Edelman; Sanjeevani Arora Journal: Cancer Treat Rev Date: 2022-01-05 Impact factor: 13.608
Authors: Stergios Boussios; Michele Moschetta; Peeter Karihtala; Eleftherios P Samartzis; Matin Sheriff; George Pappas-Gogos; Mehmet Akif Ozturk; Mario Uccello; Afroditi Karathanasi; Michail Tringos; Elie Rassy; Nicholas Pavlidis Journal: Ann Transl Med Date: 2020-12